HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marja Heiskala Selected Research

IMO-2055

4/2015Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marja Heiskala Research Topics

Disease

1Neoplasms (Cancer)
01/2019
1Colorectal Neoplasms (Colorectal Cancer)
04/2015
1Neuroendocrine Tumors (Neuroendocrine Tumor)
01/2010

Drug/Important Bio-Agent (IBA)

1ChemokinesIBA
01/2019
1IMO-2055IBA
04/2015
1Cetuximab (Erbitux)FDA Link
04/2015
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2010

Therapy/Procedure

1Drug Therapy (Chemotherapy)
04/2015